Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

<ul><li>Bio-Techne had a weak quarter, with revenues below market expectations.</li><li>Its revenue growth was not up to the mark despite the key drivers being physician uptake, utilization of its ExoDx prostate test, and increased demand for its cell therapy workflow solutions.</li><li>Their Exosome Diagnostics business remained extremely strong in the quarter due to a better marketing message, a stronger commercial team, and the recently modified Medicare LCD, which generated significant test volume and revenue growth.</li></ul>

Bio-Techne had a weak quarter, with revenues below market expectations.Its revenue growth was not up to the mark despite the key drivers being physician uptake, utilization of its ExoDx prostate test, and increased demand for its cell therapy workflow solutions.Their Exosome Diagnostics business remained extremely strong in the quarter due to a better marketing message, a stronger commercial team, and the recently modified Medicare LCD, which generated significant test volume and revenue growth.

Bio-Techne Corporation: Collaboration With Lunaphore & Other Drivers

<ul><li>Bio-Techne delivered a disappointing result in the last quarter while failing to meet Wall Street expectations in terms of revenues as well as earnings.</li><li>The company also noticed the strongest effects of decreasing biotech spending in Q2 in North America.</li><li>The multiyear growth rates in North America remain in double digits and are consistent with its long-term objectives.</li></ul>

Bio-Techne delivered a disappointing result in the last quarter while failing to meet Wall Street expectations in terms of revenues as well as earnings.The company also noticed the strongest effects of decreasing biotech spending in Q2 in North America.The multiyear growth rates in North America remain in double digits and are consistent with its long-term objectives.

Bio-Techne Corporation: Expansion RNAscope & Other Drivers

<ul><li>Bio-Techne has been going through a tough 2022 and witnessed a slow summer especially in the European markets as well as Covid-related shutdowns in China.</li><li>The company did manage to achieve some organic revenue growth but failed to meet Wall Street expectations in terms of revenues as well as earnings.</li><li>The company recently announced the release of the automated codetection assays for the company's Advanced Cell Diagnostics RNAscope system for in-situ hybridization.</li></ul>

Bio-Techne has been going through a tough 2022 and witnessed a slow summer especially in the European markets as well as Covid-related shutdowns in China.The company did manage to achieve some organic revenue growth but failed to meet Wall Street expectations in terms of revenues as well as earnings.The company recently announced the release of the automated codetection assays for the company's Advanced Cell Diagnostics RNAscope system for in-situ hybridization.

Bio-Techne Corp: Advanced Cell Diagnostics RNAscope System Developments & Other Drivers

Equity Bottom-Up

<ul>
<li>This is our first report on Bio-Techne Corporation.</li>
<li>The company delivered a strong financial performance in the past quarter, surpassing Wall Street expectations in terms of both, revenues as well as earnings.</li>
<li>Bio-Techne Corporation recently announced the unveiling of the CE-IVD marked RNAscopeTM ISH Probe High-Risk HPV Assay for neck and head cancer.</li>
</ul>


This is our first report on Bio-Techne Corporation.
The company delivered a strong financial performance in the past quarter, surpassing Wall Street expectations in terms of both, revenues as well as earnings.
Bio-Techne Corporation recently announced the unveiling of the CE-IVD marked RNAscopeTM ISH Probe High-Risk HPV Assay for neck and head cancer.


Bio-Techne Corporation: Initiation of Coverage – The Namocell Acquisition & Other Developments

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

With the S&amp;P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of the uptrends that began in March... see charts below. Therefore, we continue to have a bullish outlook and we believe the path of least resistance remains higher. In today’s report we highlight attractive Groups and stocks within Health Care and Materials: Biotech, Large-Cap, Biotech, Mid-Cap, Gold, Western Hemisphere, Small-Cap, and Silver, Platinum.

With the S&amp;P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of the uptrends that began in March... see charts below. Therefore, we continue to have a bullish outlook and we believe the path of least resistance remains higher. In today’s report we highlight attractive Groups and stocks within Health Care and Materials: Biotech, Large-Cap, Biotech, Mid-Cap, Gold, Western Hemisphere, Small-Cap, and Silver, Platinum.

U.S. Equity Strategy: Bullish Outlook Intact

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio Techne Corp (TECH US)

Bio-Techne Corporation: Collaboration With Lunaphore & Other Drivers

Bio-Techne had a weak quarter, with revenues below market expectations. Its revenue growth was not up to the mark despite the key drivers being...

Baptista Research

Bio-Techne Corporation: Expansion RNAscope & Other Drivers

Bio-Techne delivered a disappointing result in the last quarter while failing to meet Wall Street expectations in terms of revenues as well as...

Baptista Research

Bio-Techne Corp: Advanced Cell Diagnostics RNAscope System Developments & Other Drivers

Bio-Techne has been going through a tough 2022 and witnessed a slow summer especially in the European markets as well as Covid-related shutdowns...

Baptista Research

Bio-Techne Corporation: Initiation of Coverage – The Namocell Acquisition & Other Developments

This is our first report on Bio-Techne Corporation. The company delivered a strong financial performance in the past quarter, surpassing Wall...

Baptista Research

U.S. Equity Strategy: Bullish Outlook Intact

With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)